I'm LongbridgeAI, I can summarize articles.PetVivo reported FY27 Q1 revenue of $337,572, a 13.47% increase year-over-year, while narrowing its net loss to $1.61 million. The company also announced a planned acquisition of PiezoBioMembrane and expanded its PetVivo.ai beta, highlighting improved diagnosis accuracy and lower customer acquisition costs ahead of an upcoming SaaS launch.
- PetVivo posted fiscal Q1 2027 revenue of USD 337,572, up 13.47% from a year earlier. * Net loss narrowed to USD 1.61 million, while net loss per share improved to USD 0.05. * Operating loss narrowed to USD 1.61 million as total operating expenses fell to USD 1.83 million. * Announced a planned acquisition of PiezoBioMembrane, subject to closing conditions and related financing. * Expanded PetVivo.ai beta, citing 50%-90% lower customer acquisition costs and 97% AI-powered diagnosis accuracy; SaaS launch expected soon. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PetVivo Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608141650PRIMZONEFULLFEED9810668) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)